相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- GSK has secured full global rights to Chimagen Biosciences' unnamed trispecific T-cell engager for multiple myeloma in a deal worth up to $750 million. - The preclinical asset is designed to bind T cells while targeting two tumor-associated antigens, aiming for deeper responses and better tolerability than existing engagers. - GSK plans to begin Phase 1 testing in 2027, adding to a myeloma portfolio anchored by the BCMA-directed antibody-drug conjugate Blenrep. - The deal is GSK's second with Chimagen, following the 2024 licensing of the CD19/CD20-targeted T-cell engager CMG1A46 for B-cell malignancies and autoimmune disease.
- Merck is building its next growth phase around a phase III pipeline that has nearly tripled since 2021 and a target of 20 new drug launches by 2030. - The company projects more than $70 billion in non-risk-adjusted commercial opportunity from its current pipeline by the mid-2030s, more than double Keytruda's $35 billion peak consensus estimate. - Merck and Moderna reported the first positive phase 3 result for a personalized mRNA cancer vaccine, though detailed efficacy and overall survival data remain pending. - Management expects the Keytruda loss-of-exclusivity period to resemble a shallow dip or hill with a quick return to growth rather than a revenue cliff.
- Immuneering Corporation names Andrew Gengos, former CFO of Terns Pharmaceuticals, as its new Chief Financial Officer effective July 16, 2026. - Gengos brings over 25 years of biotech leadership experience, including roles at Amgen, Athira Pharma, and Cyteir Therapeutics, and was at Terns during its $6.7 billion acquisition by Merck. - He will oversee financial strategy and corporate development as the company advances atebimetinib, its lead Deep Cyclic Inhibitor, through the Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer. - Atebimetinib is an oral, once-daily MEK inhibitor designed to improve overall survival in RAS, RAF, and other MAPK-driven cancers through durable tumor shrinkage, cachexia counteraction, and minimized side effects.
- CVC Capital Partners has offered €52 per share to acquire the remaining 48.2% of Recordati shares, valuing the deal at €10.9 billion. - The acquisition would give CVC full control of the Italian pharmaceutical company, which already holds a 51.8% controlling stake acquired in 2018. - Recordati's strong financial performance in 2025 included 11.8% revenue growth to €2.6 billion, driven primarily by a 29.7% increase in rare disease drug sales. - The proposed takeover comes amid increased pharmaceutical M&A activity, with companies seeking to strengthen pipelines ahead of patent expiries.
- First Turn Management disclosed a $35.23 million new position in Terns Pharmaceuticals, acquiring 872,049 shares as the biotech's stock surged 826.2% over the previous year. - Terns updated its corporate presentation with refreshed pipeline timelines for its oncology and metabolic disease programs, including TERN-701 for chronic myeloid leukemia and NASH-focused candidates. - The company was selected for inclusion in a STOXX benchmark index effective March 23, 2026, potentially supporting trading liquidity and institutional interest. - Despite the momentum, analysts note concerns around the company's zero revenue, continuing losses of approximately $94 million, and recent equity dilution from a $650 million follow-on offering.
- Terns Pharmaceuticals successfully closed an underwritten public offering of 18,687,500 shares at $40.00 per share, raising gross proceeds of $747.5 million. - The clinical-stage oncology company will use the funds to advance research, clinical trials, and manufacturing of TERN-701, a highly selective allosteric BCR-ABL inhibitor. - TERN-701 is being developed as a potential best-in-disease treatment for chronic myeloid leukemia (CML) with improved efficacy, safety, and convenience over existing therapies. - The offering included full exercise of underwriters' option for additional shares, with Jefferies, TD Cowen, and Leerink Partners serving as lead book-running managers.
- TERN-701 achieved a 74% major molecular response rate at 24 weeks in chronic myeloid leukemia patients who had received prior treatments, significantly outperforming Novartis' Scemblix which showed 25% in similar populations. - The experimental drug demonstrated a favorable safety profile with only 32% of patients experiencing Grade 3 adverse events and no occurrence of high blood pressure or pancreatitis side effects associated with competing treatments. - Among 28 evaluable patients who had previously failed a median of three prior therapies, 64% achieved major molecular response, suggesting TERN-701 could potentially challenge the dominance of established CML treatments. - The drug works by blocking BCR-ABL signaling through a novel mechanism that changes the molecule's shape, potentially reducing off-target interactions that cause severe side effects.
- The chronic myelogenous leukemia treatment market is expected to experience significant growth through 2032, driven by increasing disease prevalence and multiple recent FDA approvals. - Recent regulatory milestones include FDA approvals for Cipla's nilotinib capsules, Marks Shorla's oral liquid imatinib formulation, and Novartis's accelerated approval for Scemblix in newly diagnosed patients. - The market features a robust pipeline of emerging therapies from companies including Enliven Therapeutics, Terns Pharmaceuticals, and Ascentage Pharma targeting unmet needs in resistant cases. - Current epidemiological data shows approximately 9,280 new CML diagnoses expected in the US in 2024, with 85-90% of patients diagnosed during the chronic phase.
- Over 80 companies are actively developing treatments for Non-Alcoholic Steatohepatitis (NASH), with Inventiva Pharma and Cirius Therapeutics leading with Phase III candidates lanifibranor and MSDC-0602K respectively. - Lanifibranor, a triple PPAR agonist with FDA Breakthrough Therapy designation, demonstrates significant anti-inflammatory and antifibrotic properties, while MSDC-0602K selectively modulates the mitochondrial pyruvate carrier to improve metabolic parameters. - Novel therapeutic approaches include Terns Pharmaceuticals' THR-β agonist TERN-501 and HighTide Biopharma's HTD1801, both showing promising results in reducing liver fat and improving metabolic markers in Phase II trials.
- TERN-701, an oral BCR-ABL inhibitor for chronic myeloid leukemia, completes dose escalation phase with promising safety profile and molecular responses in heavily pre-treated patients. - TERN-601, an oral GLP-1 receptor agonist for obesity, advances to Phase 2 FALCON trial with innovative titration strategy, targeting competitive weight loss outcomes. - Drug interaction studies reveal TERN-701's favorable safety profile with common medications, marking a key differentiation in the allosteric TKI class.
